AK112-101
03 Nov 2020
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112.
AK112-101
Acronym:
AK112-101
ACTRN/NCT /ethics:
NCT04047290
Scientific title:
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors
Sponsor / Cooperative group:
AkesoBio
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-08-15 |
| Anticipated End Date | 2022-12-30 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Anna Mislang |
| Recruitment Status | Recruiting |